Fig 1: Features of the hyperprogressive disease.In patient No. 14, who showed hyperprogressive disease: radiographic and H&E staining images before (A) and after (B) neoadjuvant therapy. C Multiplex immunofluorescence images of the tumour site before and after neoadjuvant therapy. Primary antibodies targeting CD163, CD68, PD-1, CD8, PD-L1, and Pan-CK were used. Nuclei acids were stained with DAPI. D Comparison of fluorescence intensity for CD8+ and CD163+ cells. After staining, slides were scanned, and multilayer images were used for quantitative image analysis. The quantities of various cell populations were expressed as the number of stained cells per square millimetre in all nucleated cells. Due to limited tumour tissue obtained by biopsy, immunofluorescence experiments were performed without repetition. Source data are provided as a Source Data file.
Fig 2: Immunohistochemical staining for immune cell analysis in primary tracheobronchial neoplasm. Representative picture of cells expressing PD-L1 (A,G), FOXP3 (B,H), CD8 (C,I), CD16 (D,J), CD68 (E,K), and CD163 (F,L) in ACC and SCC. Scale bars =60 µm (×200). ACC, adenoid cystic carcinoma; SCC, squamous cell carcinoma.
Fig 3: Immune infiltration analyses. (A–C) Detection of infiltrated macrophages, CD8+ T cells and CD4+ T cells in 4 responders/CBP_low and 4 non-responder/CBP_high to immunotherapy in the PKUCH cohort. (D–F) The M1/M2 ratio, CD8+ T cell proportion and CD4+ T cell proportion in 4 responders/CBP_low and 4 non-responders/CBP_high to immunotherapy. (G–I) Kaplan–Meier curves for the OS of GC patients in different groups classified by the median of CD68, CD8 and CD4 levels from a PKUCH cohort.
Fig 4: Immune cell subset characteristics in the tumor microenvironment. (A) Multiple fluorescence immunohistochemical images for tumor (panCK, Abcam, ab7753), T cells (CD8, Abcam, ab178089), macrophages (CD68/HLA-DR, Abcam, ab213363/Abcam, ab92511), and NK cells (CD56, Abcam, ab75813) in the vaginal stump bump sample. Multiplex stained slides were scanned using a Vectra Polaris Quantitative Pathology Imaging System (Akoya Biosciences) at 20 nm wavelength intervals from 440 to 780 nm with a fixed exposure time and an absolute magnification of ×200. (B) Quantitative analysis of the immune composition in the tumor and stroma. (C) Percentage of immunoreactive cells in the tumor component. panCK, pan-cytokeratin; CD8, cluster of differentiation 8; CD68, cluster of differentiation 68; HLA-DR, human leukocyte antigen-DR isotype; CD56, cluster of differentiation 56.
Fig 5: The immune cell biomarkers of tumor tissue samples from patients treated with neoadjuvant immunochemotherapy and chemotherapy alone. Multiplex immunofluorescence staining was performed for immune cell biomarkers, as denoted by different colors, in specimens of NSCLC patients treated with neoadjuvant therapy (surgical resection after NAT). The density and percentage of CD8+ (A), CD68+CD163- (B), and PD-L1+CD68+ (C) immune cells in the tumor center or stroma were analyzed. Representative images showing the multiplex immunofluorescence staining for identifying the immune cell subsets in the tumor immune microenvironment. Io+Chemo, immunochemotherapy; Chemo, chemotherapy; *P <0.05; ns, no statistical significance.
Supplier Page from Abcam for Anti-CD8 alpha antibody [SP239]